Skip to NavigationSkip to content

Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

Published on 12/02/19 at 09:57am

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 trial, causing shares in the company to fall by as much as 4%.

Gilead’s treatment for Nonalcoholic Steatohepatitis (NASH), a drug called selonsertib, did not meet its primary endpoint in a randomised, double-blind, placebo controlled Phase 3 trial involving 877 patients.

Of the 877 patients, 14.4% of those receiving 18 mg of selonsertib, compared to 12.5% who received 6mg achieved a ≥ 1-stage improvement in fibrosis after 48 weeks of treatment. Meanwhile 12.8% of those who received the placebo achieved similar results.

“While we are disappointed that the STELLAR-4 study did not achieve its primary endpoint, we remain committed to advancing therapies for patients with advanced fibrosis due to NASH, where there is a significant unmet need for effective and well-tolerated treatments,” said Dr John McHutchison, Chief Scientific Officer, Head of Research and Development, Gilead.

Analysts have projected the NASH market to be worth between $20 billion and $35 billion as cases of the fatty liver disease are on the rise.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches